Pharma Mar, S.A. (PHMMF)

Market Cap	1.65B
Revenue (ttm)	189.96M
Net Income (ttm)	21.48M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	77.01
Forward PE	23.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,166
Average Volume	1,784
Open	93.88
Previous Close	104.49
Day's Range	93.81 - 93.95
52-Week Range	31.15 - 105.60
Beta	-0.11
RSI	40.63
Earnings Date	Jul 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHMMF

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.

Financial numbers in EUR